Filter by
Cerebiome® exerts a positive influence on the gut microbiota of individuals with mild anxiety, new study findsApsen Farmaceutica, Lallemand Health Solutions’ commercial partner in Brazil, is publishing new positive results on the influence of Cerebiome® on the gut microbiota of individuals with mild anxiety. The positive influence of Cerebiome® on the gut microbiota of individuals with […]
Apr 25, 2023
SYLVIE BINDA PRESENTS AT THE JOURNÉE MICROBIOTES ET SANTÉSylvie Binda, Vice President Research and Development at Lallemand Health Solutions will contribute to the 6th edition of the Journée Microbiotes et Santé (Microbiota and Health Day), organized by Lyonbiopôle in partnership with the Alliance Promotion Microbiote, scheduled for March […]
Mar 1, 2023
SCIENTIFIC EXCHANGE 2023: A Journey to The Top; The Past, Present, and Future of Probiotics Applications in Human WellbeingRenowned scientists from around the world gathered in Montreal at the occasion of the 12th edition of Scientific Exchange event, organized by the Rosell® Institute for Microbiome and Probiotics by Lallemand, on February 15-16. The SciEx conference program and poster […]
Feb 20, 2023
Lallemand, An Active Member of The Grand Défi Ferments Du Futur Consortium: Innovating For the Food of TomorrowLallemand is joining forces by getting involved in the steering committee of the Grand Défi Ferments du Futur[1], a highly strategic program that aims to accelerate research and innovation in the field of ferments and fermented foods to meet the […]
Dec 19, 2022
Sylvie Binda elected on the Pharmabiotic Research Institute board of directorsSylvie Binda, vice-president research and development at Lallemand Health Solutions has been elected as a new member of the board of directors of Pharmabiotic Research Institute (PRI), as announced during the annual general assembly and member event, in Rotterdam, the […]
Dec 9, 2022
Lallemand Health Solutions Appoints Vincent Thomas, Ph.D. as R&D Innovation DirectorVincent Thomas, Ph.D., is joining Lallemand Health Solutions as R&D Innovation Director. Mr. Thomas will start his new position on December 5 and report to Sylvie Binda, Vice-President R&D. “We are very pleased that Mr. Thomas has accepted to come […]
Nov 29, 2022
Lallemand Health Solutions supports the innovative French Gut Project to accelerate microbiota scienceLallemand Health Solutions is joining forces with the French Gut Project, which aims to collect 100,000 French intestinal metagenomes for analysis, and the associated nutritional and clinical data, to accelerate microbiota science and innovation in health and nutrition. This ambitious […]
Sep 15, 2022
Lallemand Health Solutions Opens the SEMiPyP Congress With An Update on IBacilluS+: A Highly Documented Probiotic Formula for Serious Gut ConditionsSara Caballero Calero, M.Sc. Clinical Research Specialist at the Rosell® Institute from Microbiome and Probiotics by Lallemand, will be the guest speaker at the inauguration conference of the XIII Workshop of the Sociedad Española de Microbiota, Probióticos y Prebióticos (SEMiPyP). […]
May 31, 2022
Having IMPACTT 2022: The Rosell® Institute for Microbiome and Probiotics Renews Its Platinum SponsorshipThe Rosell® Institute for Microbiome and Probiotics by Lallemand reconducts its platinum sponsorship of the Canadian microbiome symposium, Having IMPACTT, for a second year in a row. Having IMPACTT 2: Advancing Microbiome Research will take place June 2 and 3, […]
May 26, 2022
Lallemand Health Solutions at Pharmabiotics: Join in To Learn More About Discovery, Development & Preclinical ResearchAnnie Tremblay, Scientific Writer at Lallemand Health Solutions will present “Preclinical and Clinical Studies Shed Light on Potential Modes of Action of L. rhamnosus HA-114 in Metabolic Regulation and Neuroprotection” at the Pharmabiotics Conference and Partnering 2022, in Lyon, France, […]
Apr 11, 2022